TGF-β1 factor is considered a tumor inhibitor in precancerous lesions, but different mutations or loss of expression of TGF-β1 receptors and SMAD proteins can switch it, and TGF-β1 might be converted into a tumor promoter in later stages of cervical neoplasia. Here, TGFB1 is linked to neoplasm.